CERO THERAPEUTICS HOLDINGS, INC.

Distress signal

Moderate confidence (50%)

Updated Sep 18, 2026, 01:34 AM

What is happening

Derived by rule set status-rules-2026.09.7

An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.

Latest material event: CERO THERAPEUTICS HOLDINGS, INC. was delisted from its exchange (Jul 13, 2026)

Every material event, newest first. History is never overwritten.

CERO THERAPEUTICS HOLDINGS, INC. was delisted from its exchange
Jul 13, 2026
Delisting effective
- SEC EDGAR — “X0203 0001354457 Nasdaq Stock Market LLC 0001870404 CERO THERAPEUTICS HOLDINGS, INC. 333-259491 2201 Broadway, Suite 705 Oakland CA CALIFORNIA 94612 4159940582 Common Stock, Warrants 17 CFR 240.12d2-2(b) Aravind Menon Hearings Advisor 2026-07-13”
CERO THERAPEUTICS HOLDINGS, INC. received a delisting notice from its exchange
Jan 29, 2026
Delisting notice received
- SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on October 29, 2025, CERo Therapeutics Holdings, Inc., a Delaware corporation (the Company ), received the determination from the Nasdaq Hearing Panel (the Panel ) to delist the securities of the Company from the Nasdaq Stock Market, LLC ( Nasdaq ) and suspend trading of the Company s securities, effective at the opening of trading on October 31, 2025. Following such determination, the Company appealed the Panel s decision to the Nasdaq Listing and Hearing Rev…”

Every material source used to build this profile.

SEC Company Submissions (TIER 1 · UNVERIFIED)
CERO THERAPEUTICS HOLDINGS, INC. — Biological Products, (No Diagnostic Substances) (SIC 2836) — SOUTH SAN FRANCISCO, CA
View source record
SEC EDGAR (TIER 1 · UNVERIFIED)
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on October 29, 2025, CERo Therapeutics Holdings, Inc., a Delaware corporation (the Company ), received the determination from the Nasdaq Hearing Panel (the Panel ) to delist the securities of the Company from the Nasdaq Stock Market, LLC ( Nasdaq ) and suspend trading of the Company s securities, effective at the opening of trading on October 31, 2025. Following such determination, the Company appealed the Panel s decision to the Nasdaq Listing and Hearing Rev…
View source record
SEC EDGAR (TIER 1 · UNVERIFIED)
X0203 0001354457 Nasdaq Stock Market LLC 0001870404 CERO THERAPEUTICS HOLDINGS, INC. 333-259491 2201 Broadway, Suite 705 Oakland CA CALIFORNIA 94612 4159940582 Common Stock, Warrants 17 CFR 240.12d2-2(b) Aravind Menon Hearings Advisor 2026-07-13
View source record

Every derived status, with the rule that produced it.

DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:29 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:14 AM
An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.
DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 15, 2026, 12:33 PM
The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.
DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 14, 2026, 04:46 PM
The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.
DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 11, 2026, 12:03 AM
The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.
UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 03:21 AM
The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.